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The gamma and Erlang density functions describe a large class of lagged, right-skewed distribu- 
tions. The Erlang distribution has been shown to be the analytic solution for a chain of  compart- 
ments with identical rate constants. This relationship makes it useful for the analysis of  first-pass 
pulmonary drug uptake data following intravenous bolus administration and the incorporation of 
this analysis into an overall systemic drug disposition model. However, others have shown that 
one Erlang density function characterizes the residence time distribution of solutes in single tissues 
with significant systematic error, We propose a model of two Erlang density functions in parallel 
that does characterize well the arterial appearance of indocyanine green, antipyrine, and alfentanil 
administered simultaneously by right atrial bolus injection. We derive the equations that permit 
calculation of the higher order moments of  a system consisting of two parallel Erlang density 
functions and use the results of these calculations from the data for all three indicators to estimate 
pulmonary capillary blood volume and mean transit time in the dog. 
KEY WORDS: indocyanine green; antipyrine; alfentanil; tissue distribution; physiologic 
models; dogs; pulmonary uptake; pulmonary capillary blood volume; pulmonary capillary 
transit time. 
INTRODUCTION 
The drug concentration vs. time profile of  the initial arterial appearance, 
after rapid intravenous (bolus) administration, of  drugs that interact 
strongly with pulmonary tissue (e.g., basic amines) is significantly different 
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from that of drugs which have no such strong interaction (1,2). Quantitation 
of this tissue-drug interaction requires a multiple indicator dilution technique 
to account for the kinetic events representing intravascular and tissue water 
effects (3). 
A multiple indicator dilution technique using albumin, diazepam, and 
alfentanil as markers has been used by Audi et al. to estimate pulmonary 
capillary kinetics in isolated perfused dog and rabbit lungs (4,5). The tech- 
nique of Audi et al. utilizes the higher order moments of the transit time 
density function to describe the indicator outflow concentrations from 
pulmonary tissue. 
The synthetic opioid alfentanil is a basic amine with the most rapid 
onset of effect of any of the opioid drugs, hence variability in its pulmonary 
disposition may contribute to interindividual differences in drug response. 
We report the results of a study of the pulmonary uptake of alfentanil 
conducted in the intact dog using a multiple indicator dilution technique in 
which indocyanine green (ICG) and antipyrine are used to account for the 
kinetic events representing intravascular and tissue water effects, respec- 
tively. We propose a model in which the arterial appearance history of each 
of the multiple indicators is characterized by two parallel gamma distribu- 
tions, with different transit parameters, that improves upon the basic (single) 
gamma distribution model and upon the single pathway central (pulmonary) 
circulation we have used previously (6,7). 
The gamma pulmonary disposition model used in the present study is 
equivalent to the sum of two parallel Erlang frequency distributions in which 
the n parameters of the gamma distributions are rounded to the nearest 
integer value. We will show how this relationship can be exploited for the 
construction of compartmental models of in vivo drug distribution that 
include precise characterization of pulmonary drug uptake and nearly con- 
tinuous arterial drug concentration sampling. In addition, the variables from 
either the gamma or Erlang distributions can be used to calculate directly 
the higher order moments. We used the higher order moments describing 
our data to estimate pulmonary capillary kinetics in order to assess the 
ability of this proposed methodology to deal with the potentially confound- 
ing influence of recirculation on pulmonary kinetics derived in vivo. 
M E T H O D S  
Following Institutional Animal Care and Use Committee approval, we 
studied four conditioned, heart worm-free male mongrel dogs that were one 
to three years old and weighed 22 to 30 kg. Anesthesia was induced with 
methohexital (15 mg/kg) administered through an 18 g Teflon | catheter in 
a foreleg vein. After the trachea was intubated with a 9 mm tracheal tube, 
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controlled, positive-pressure ventilation was instituted and maintained 
throughout the experiment with an inspired mixture of 2% halothane in 
oxygen. A 16 g, 2 in Teflon | catheter was placed percutaneously in a femoral 
artery and a 7 Fr flow-directed pulmonary arterial catheter (Baxter-Edwards 
93A-140-7F, with a proximal port at 20 cm) was positioned through an 8 Fr 
introducer that was placed percutaneously in the right external jugular vein. 
At the onset of the study (time t = -0.05 min), ICG (5 mg in 1 ml of 
diluent), antipyrine (25 mg in one ml), and alfentanil (1 mg in 2 ml) (Janssen 
Pharmaceutica, New Jersey), were placed in a leading length of tubing and 
injected within one second through the proximal pulmonary artery catheter 
port and flushed in with 10 ml of 0.9% saline solution. Three milliliter arterial 
blood samples were collected every 0.05 min for the first minute and every 
0.1 min for the next minute using a computer-controlled roller pump 
(Masterflex, Cole-Parmer, Chicago, Illinois) with polyvinyl tubing having a 
total deadspace volume of 3 ml (in order to both minimize total collection 
system volume and to match the volume collected for each sample), running 
at 1 ml/sec for the first minute and 0.5 ml/sec for the next minute, and a 
chromatography fraction collector (Model 203, Gilson, Middleton, Wiscon- 
sin). This collection system was actuated just prior to the injection time (t = 
-0.05 min) and blood withdrawn before time t = 0 was discarded in order 
to correct the discrepancy created by the catheter transit delay. Huang et 
al. (8) have indicated that laminar flow within such catheter systems may 
affect results only when the system's flow to volume ratio is much smaller 
than ours. Tests performed in our laboratory on our system confirms these 
observations and that deviation from true plug-flow is trivial. Subsequent 
arterial blood samples were drawn manually at 0.5 min intervals to 4 min. 
Dogs were euthanatized by intravenous injection of saturated KC1 solution 
while anesthetized at the conclusion of the study. 
Hematocrits were determined on blood obtained before and at one and 
two minutes after drug injection. Plasma drug concentrations were converted 
to blood concentrations to facilitate the estimation of the contributions of 
blood flow and transcapillary diffusion to intercompartmental clearance and 
to allow estimation of intravascular volumes. 
Plasma ICG concentrations of all samples were measured on the day 
of the study by HPLC (9). This method has been modified in our laboratory 
by the use of two detector/integrator pairs in series, one monitoring absorb- 
ance of desmethyldiazepam (the internal standard) at 254 nm and one moni- 
toring absorbance of ICG at 786 nm (6). This produces a linear ICG 
measurement range of 0.2/lg/ml to 20.00 pg/ml with coefficients of varia- 
tion of 5% or less. Plasma ICG concentrations were converted to blood 
concentrations by multiplying plasma ICG concentrations by one minus the 
hematocrit, as ICG does not partition into erythrocytes. 
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Plasma antipyrine concentrations of all samples were measured in dupli- 
cate using an HPLC technique similar to our barbiturate assay (7,10). 
Plasma samples were extracted in duplicate with solid phase extraction col- 
umns using 4-aminoantipyrine as the internal standard. Samples were eluted 
isocratically from a Radial-Pak C18 cartridge (Waters Associates, Milford, 
Massachusetts) and absorbance monitored at 254 nm. The antipyrine 
method is linear from 0.10 pg/ml to 10.00 pg/ml, with coefficients of varia- 
tion of 5% or less. 
Plasma alfentanil concentrations were measured using an adaptation of 
the GC-NPD technique of BjSrkman and Stanski (11). Plasma samples were 
extracted in duplicate with solid phase extraction columns using fentanyl as 
the internal standard. The assay has sensitivity over a linear range of 
50 ng/ml to 5000 ng/ml, with coefficients of variation of 7% or less 
throughout the range. 
Data Analysis 
In general, models that describe drug concentration histories measured 
at an organ outflow, following impulse inflow administration, must be uni- 
modal, asymmetric and right-skewed. Compartmental flow models are in 
this class and give, among others, the Erlang density function. Figure la 
shows the form of a tanks-in-series or linear chain of n identical compart- 
ments with exiting rate constant k. The solution for a linear chain obtained 
by successive integration for the rate of exit from compartment n is given 
by: 
IC" t n - I  
f ( t ) =  9 e -k' (1) 
( n -  1)l 
where 
o~~ d r =  1 (2) 
This is an Erlang density function which is a special case of the gamma 
distribution function: 
k" - t"-  t 
f ( t )  = 9 e -kt (3) 
F(n) 
with n restricted to integer values. These functions describe a drug or indi- 
cator concentration history C(t): 
C ( t )  = A .  f ( t )  (4) 
where A is the area under the plasma or blood drug concentration vs. time 
relationship (AUC or zeroeth moment). Higher order moments describe the 
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Fig. 1. (a) Schematic of a flow-through system modeled as a linear chain (or tanks- 
in-series) in which compartments (V1) are linked in series by transfer rate constants 
(k) of identical value are interposed between the sites of administration and sam- 
piing. (b) Schematic of a flow-through system modeled as a pair of linear chains or 
(tanks-in-series) interposed between the sites of administration and sampling. Flow 
is divided between pathways p and q (shown as transfer constants of unequal size 
connoting differential apportionment of flow) each having a distinct number of 
compartments (F1, SI ) and linked in series by transfer rate constants (kl, k2) that 
are unique to each pathway but identical within it. 
characteristics o f  the concentration vs. time profile. The first moment  
estimates the mean transit time (mtt), the second central moment  estimates 
the variance (or2), and the third central moment  estimates the skewness (8). 
Using the Erlang (gamma)  function, which describes right-skewed, lagged 
distributions (e.g., single-pass drug concentration history), the higher order 
moments  are easily calculated (using n and k f rom Eqs. (1) or (3)) as follows: 
n 
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2 . n  
8 -  k3 (7) 
Cardiac output (C.O., which is the flow through the central or pulmon- 
ary circulation) is estimated from the ICG (dye) dilution curve (12): 
Dose 
c . o .  - (8) 
AUC 
The apparent distribution volume (Vd) between the right atrial injec- 
tion site and the arterial sampling site can be estimated from: 
Vd=mtt .  C.O. (9) 
For ICG, this Vd is an estimate of the central or thoracic plasma volume, 
which is also an estimate of central blood volume when it is divided by (1- 
Hct). For drugs or indicators that readily leave the intravascular space to 
partition into tissues, the difference between the intravascular volume (i.e., 
the Vd for ICG) and the Vd for the drug or indicator that distributes to 
tissue provides an estimate of the apparent pulmonary tissue volume. 
Audi et al. have described a method of estimating pulmonary capillary 
blood volume using a multiple indicator dilution technique in which one 
indicator is an intravascular reference marker (e.g., ICG) and at least two 
other indicators which variably distribute to pulmonary tissue in a flow- 
limited manner (4,5). They reasoned that the different extravascular kinetics 
of these markers arise solely during their pulmonary capillary sojourns. In 
the present study, the two flow-limited markers used were antipyrine and 
alfentanil. Antipyrine has long been used as a flow-limited tissue distribution 
marker that provides an estimate of tissue water space, including that of the 
lung (1 3,14). Our previous work and that of others indicate that the tissue 
distribution of alfentanil is also largely flow limited (15,16). 
From the respective outflow indicator concentration histories, the mtt, 
o "z, and 8 are estimated. The extravascular mtt,, 002, and 6, of the flow- 
limited markers (antipyrine and alfentanil) are derived by subtracting from 
the respective values for the drugs those values for the intravascular indicator 
(ICG) (4,5): 
mtte = m t t d r u g  - -  mthcc (10) 
2_ 2 002 (11) 00e -- 00drug- 1CG 
~e = ~ d r u g -  6ICG (12) 
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Such extravascular kinetics of two or more markers can be used to 
solve, by an iterative, nonlinear, least squares estimation technique, the 
following equations (4): 
mttpc / 
m t tpc / 
in order to derive estimates for pulmonary capillary mtt  (mttpr variance 
(o'~), and  skewness (~pc) for each extravascular indicator (ei). 
Figure 1 b shows a model with two lumped, parallel pathways interposed 
between a pre-tissue injection site and a post-tissue/capillary sampling site; 
the heterogeneous circulation found in many organs is most simply described 
by two parallel pathways. The corresponding Erlang distribution is: 
C ( t ) = A  ~ k ~ "  t "~-~ k~  ~" t n2-1 
9 9 e -k ' t  + A2" e-'*'2' ( 1 5 )  
( n , -  1)! (n2- 1)! 
or 
C( t )  = A1" f l ( t )  + A2" f z ( t )  (16) 
where the AUC is A1 plus A2 and the fractional flow through each pathway 
is the respective fractional AUC: 
Ai A2 
p = - -  and q -  - -  (17) 
A1 +A2 AI +A2 
with p + q = 1. 
The system mtt  is calculated using the first moment of the function 
describing the drug concentration vs. time relationship: 
fo m t t =  t" f ( t )  dt (18) 
but for a system with two parallel pathways, the mtt  for the system is the 
sum of the flow-weighted mtts for the individual circuits: 
f ( t )  = p .  f~(t) + q .  f2(t) (19) 
mtt  =p 9 mth  + q" mtt2 (20) 
In addition to the contributions of the variance seen in each pathway, 
one must consider the additional variance contributed by the relative separa- 
tion of the mtts in order to obtain the system's variance. Thus, the system 
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variance (or second central moment) in general is: 
fo cr 2= ( t - m t t )  2 " f ( t )  dt (21) 
and for two parallel paths: 
fo o-2= [ t - ( p .  mtt, +q.  mtt2)] 2. [p .f~(t)+q" f2(t)] dt (22) 
which, after integration, can be reduced algebraically to: 
o-2 =po-~ + qo-~ + pq(mtt2- tutti) 2 (23) 
For skewness of the overall parallel system, one must also consider the 
additional skewness contributed by the separation of the individual mtts and 
variances. In general, skewness (or third central moment) is defined as: 
8 = ( t -  mtt) 3. f ( t )  dt (24) 
and for two parallel paths: 
fo t~= [ t - ( p .  mth +q.  mtt2)] 3" [p " f l ( t )+q"  f2(t)] dt (25) 
which, after integration, can be reduced algebraically to: 
=prt + q~2 + pq[ (p - q)(mtt2- mttl) 3 + 3(o -2 - 0 "2)(mtt2- rnth ) ] (26) 
Arterial drug/marker concentration vs. time data prior to recirculation 
were fitted to a single and the sum of two gamma distributions using 
TableCurve2D ver 3.0 (Jandel Scientific, San Rafael, California) on a Pen- 
tium-based PC using constant standard deviation weighting. Model selection 
between single or dual pathway models was made on the bases of visual 
inspection of fit quality, adjusted r 2, and Akaike information criteria (AIC). 
The values of n~ and n2 were then rounded to the nearest integer and the 
data were fit to a single or the sum of two Erlang distributions [Eqs. (4) 
and (16)] to derive the parameters for the equivalent compartmental flow 
models. The effect of recirculation of a suddenly injected intravascular 
marker, such as ICG, is not evident until the marker concentration has 
nearly returned to baseline: monoexponential extrapolation from a point of 
the downlimb of the first-pass data at a time when the baseline is being 
approached, but prior to a time when any decrease in slope is evident, 
assures that recirculated indicator is not being included in the first-pass 
concentration history (12). Since the downlimb of a gamma distribution 
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function is a monoexponential decay, we applied these classical criteria for 
defining first-pass data to our analysis of data with the gamma and Erlang 
distribution functions. 
Two sets of Eqs. (13) and (14) (one for each extravascular marker, 
antipyrine and alfentanil) were fitted simultaneously using the nonlinear, 
least-squares fitting routine of SAAM II (SAAM Institute, Seattle, Washing- 
ton). Mean values for the estimates of pulmonary capillary transit were 
derived using a naive pooled data technique in which data from all four 
dogs were simultaneously fit to a single model using relative reciprocal 
weighting as the square of the reciprocal of the standard deviation (SD) of 
the observed data, assuming a fractional SD of 0.2. 
A functional RBC/plasma partition ratio for antipyrine and alfentanil 
can be estimated from Eq. (8) and the relationship that blood indicator 
concentration is equal to the sum of the concentrations in plasma and RBCs 
weighted for their respective fraction of blood volume. The product of the 
cardiac output and the AUC for the plasma concentration vs. time curve 
equals dose when the RBC/plasma partitioning for the indicator is unity. 
From these relationships, a functional estimate of the RBC/plasma partition 
for an indicator or drug can be determined from in vivo data according to 
the following formula: 
RBC Adm. Dose 1 - Hot 
(27) 
plasma AUC.  C.O.. Hot Hot 
Estimates of the RBC/plasma partition coefficient thus derived should be 
considered functional in that they satisfy best the assumptions of the multiple 
indicator dilution technique in each study. The advantage of using a 
RBC/plasma partition ratio determined in vivo needs to be tempered by the 
consideration of the many possible confounding factors that may affect 
estimation of the first-pass AUC. 
RESULTS 
Figures 2a-d show the measured concentration histories and fitted 
single gamma or Erlang distributions (the fitted gamma and Erlang functions 
are indistinguishable so only a single line is shown) for all three indicators 
in all four dogs and Figs. 3a-d show the results for the sum of  two gamma 
or Erlang distributions. Note that the single gamma or Erlang fits have 
systematic errors (Figs. 2a-d), suggesting model misspecification that does 
not exist in the double gamma or Erlang distribution (Figs. 3a-d). The 
selection of the double gamma distribution model over the single gamma 
distribution model was further based on improvement in adjusted r ~ and 
AIC. The average improvements in adjusted r 2 for the ICG, antipyrine, and 
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alfentanil models were 1.5%, 2.3%, and 3.4%, respectively. The adjusted r z 
for the double gamma distribution models were 0.995 or higher while those 
for the single gamma model function were as low as 0.920. In no instance 
was the improvement in unadjusted r 2 between a sum of two gamma distribu- 
tions vs. the sum of two Erlang distributions more than 0.004%, making the 
respective lines for the predicted functions in Figs. 3a-d appear superim- 
posed. The AIC also supported the dual gamma distribution model over the 
single gamma model in all of the alfentanil data sets, all but one of the 
antipyrine data sets (dog 4), and all but one of the ICG data sets (dog 3). 
Despite the significantly improved fits of the dual gamma distribution 
function models over that of the single gamma distribution function models, 
the standard error of the parameter estimates for the gamma functions with 
the longer MTT were often quite large with FSDs ranging from 0.23-4.7 for 
ICG, 1.1-3.7 for antipyrine, and 0.07-2.2 for alfentanil. The high variance 
associated with these parameters was not markedly affected by the number 
of data points, or the cut-off for recirculation of drug. Fitting simulated 
data (with random error) of these models, with no recirculation and up to 
100 data points, showed some improvement in the FSDs of the parameters, 
but frequently they remained above unity. Examination of the correlation 
matrices showed positive and negative correlations of 0.9 and above for all 
parameters in many instances, suggesting that the model solutions may not 
be unique. 
From Table I it can be seen that there is good agreement between the 
thermal dilution cardiac outputs and those obtained from the fitted ICG 
gamma or Erlang functions despite differing methodologies (heat content 
vs. dye), sampling protocols (continuous, or 0.3 Hz, temperature sensing in 
the pulmonary artery vs. 3 second collections from the femoral artery via a 
roller pump), and AUC estimation algorithms. From Eq. (27) the mean 
estimates for the RBC/plasma partitioning of antipyrine and alfentanil 
under these in vivo conditions were 0.87 and 0.46, respectively. 
Table I. Subject Information Including Cardiac Output by Dye Dilution (ICG), Thermo- 
dilution (TD), Central Blood Volume (ICG), and Pulmonary Tissue Volume (Antipyrine) 
C.O, lco C.O.,rr, Central blood Pulm. tis. 
Hct Wt (kg) (L/min) (L/min) VolJ (L) Vol. b (L) 
Dog 1 0.38 25 1.89 1.89 0,626 0.058 
Dog 2 0.37 22 1.98 1.86 0.564 0.074 
Dog 3 0.42 30 3.70 3.64 0.796 0.146 
Dog 4 0.35 30 2.81 2.77 0.568 0.134 
Mean 0.38 26.8 2.60 2.54 0.638 0.103 
•  0.03 4.0 0.85 0.85 0,109 0.044 
~Calculated as the product of ICG mtt and C.O. 
bCalculated as the product of antipyrine mtt and C.O. minus central blood volume. 
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Table lI. Mean • SD of Central Circulation Parallel Erlang Parameters, and the Composite 
mtt, Variance (Square Root), and Skewedness (Cube Root) for the Various Drugs and that 
Derived for the Capillary Blood 
ICG Antipyrine Alfentanil Capillary Blood 
n, 22.54-4.2 21.24-6.6 15.54-2.6 - -  
k~ 116.1 4- 27.9 89.6 4- 23.8 60.0 4- 7.6 - -  
A, 0.94-0.4 5.8 • 0.19• - -  
n2 13.04-1.4 10.24-3.2 6.54-1.3 - -  
k2 52.54- 1 2 . 9  33.44-16.0 16.94-6.0 - -  
A2 1.1 4-0.4 5.1 4-3.8 0.344-0.19 - -  
mtt  (min) 0.23 4- 0.06 0.28 4- 0.06 0.35 4- 0.08 0.018 4- 0.010 
variance (min) 0.066• 0.0954-0.032 0.154-0.04 0.0164-0.015 
skew (rain) 0.16 4- 0.03 0.21 4- 0.05 0.28 4- 0.06 0.019 4- 0.020 
In Table II are the parameter estimates of the sum of the first two 
Erlang functions derived from the least squares fits for all three drugs. These 
estimates were used to derive the means and standard deviations for the mtt, 
variance, and skewness of the first pass concentration vs. time curves for 
ICG, antipyrine, and alfentanil seen in Table II. It is readily apparent in 
Figs. 2 and 3 that the transit time through the central circulation and the 
lungs for ICG is less than that for antipyrine which, in turn, is less than 
that for alfentanil in all dogs. Subtracting the respective values for ICG 
from those for alfentanil and antipyrine, one obtains the mtt, variance and 
skewness for the extravascular concentration-time density function [Eqs. 
(10-12)]; the means and standard deviations are shown in Table II. In Fig. 
4 the individual values for these extravascular parameters are plotted with 
the best fit of the functions delineated in Eqs. (13) and (14). The estimates 
of pulmonary capillary mtt, variance, and skewness derived from this fit 
appear in Table II. 
DISCUSSION 
The results of this analysis suggest that the considerable heterogeneity 
in the distribution of transit times in the pulmonary circulation may be 
described by two parallel, lumped pathways with different transit character- 
istics. Gamma and Erlang distributions perform equivalently in such a paral- 
lel system in their ability to characterize the lagged, right-skewed, first-pass 
drug concentration histories of multiple indicators. They also complement 
each other because they have mutually exclusive advantages. The sum of 
gammas is advantageous because the n parameters can be readily optimized, 
whereas the ns in the sum of Erlangs are not because most data-fitting 
software do not have parameter optimization algorithms restricted to integer 
increments. The sum of Erlangs is advantageous because it provides a means 
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Fig. 4. The relationship of the extravascular mean transit time 
(abscissa) of antipyrine (open symbols) and alfentanil (closed symbols) 
vs. both the extravascular transit time variance (ordinate and upper 
symbols) and extravascular mean transit time skewness (ordinate and 
lower symbols) in each dog (dog 1, circles; dog 2, squares; dog 3, 
triangles; dog 4, diamonds). The upper solid line is predicted by the 
best fit of these data to Eq. (13) and the lower dashed line is that 
predicted by the best fit to Eq. (14). Note how the antipyrine values 
tend to cluster (pulmonary mtt=2-4  min) while those of alfentanil 
tend to separate. 
of incorporating the results of lagged, first-pass kinetics into a compartmen- 
tal model of ordinary differential equations. Thus, this approach will enable 
incorporation of an accurate depiction of first-pass pulmonary kinetics into 
models describing the subsequent systemic disposition. These models can 
also be used to construct pharmacokinetic models which account for the 
first arterial appearance of drug in addition to systemic disposition. 
Analysis of single-pass indicator dilution data obtained only from the 
tissue effluent, such as in this pulmonary first-pass study, requires a model 
with a time lag or delay because drug does not appear at the sampling site at 
the time of administration. A time lag is required when a model is incomplete 
because the subsystem that generates the lag has been omitted (3). The 
linear chain produces a distribution of lag times which is well-suited to 
describe drug distribution because laminar flow in the vasculature, turbu- 
lence at branch points, and the distribution of path lengths contribute 
to a continuous distribution of circulatory lags or transits. Time lags 
produced by chains of n compartments with the same transfer coefficient 
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(i.e., the Erlang distribution) provide very good approximations of the 
partial differential equation subsystem; as n---, oo the linear chain produces 
a discrete delay (3). 
A linear compartmental chain (or tanks-in-series) was unable to charac- 
terize well the outflow from the isolated perfused liver (17). Comparison of 
mathematical organ perfusion models by Roberts et al. demonstrated that 
a single tanks-in-series model characterized hepatic outflow data with small, 
but systematic error, strongly suggesting model misspecification (17). Their 
analysis led them to advocate a parallel tubes model to better account for 
heterogeneity of organ transit times. We experienced similar difficulties (see 
Fig. 2a-d) when our pulmonary outflow data were fit with a single linear 
chain, or Erlang function, despite allowing n to vary during the curve fitting 
process. Resolution of our modeling difficulties with two parallel linear 
chains is analogous to the successful application of the parallel tube model 
to hepatic outflow data by Roberts et al. (17). 
Roberts and Weiss have recently reported a stochastic modeling tech- 
nique for tissue outflow of drug concentrations with a sampling density 
similar to that in the present study. As in the present study, these authors 
found that a mixture of two density functions gave the optimum fit to 
describe the dispersion of transit times. They used a mixture of two Gaussian 
functions rather than gamma or Erlang functions but did not report the 
standard errors of the parameter estimates nor the correlation between these 
parameters. We fit some of our current data to a sum of two Gaussian 
distribution functions and found the quality of the fits, the adjusted r 2, 
standard errors of the estimates, and the parameter correlations to be nearly 
identical to those obtained with two gamma functions. It should be noted 
that with both models, fit quality is high, but in some data sets parameter 
confidence is relatively low. This may be an indication that in some instances 
the precise parameter estimates may not be unique because of the high 
correlation between parameters. This condition should be considered when 
interpreting the significance of the individual density function making up 
the mixture. 
Audi et al. have described a technique for analyzing multiple indicator 
(including alfentanil) data from an in vitro isolated lung preparation which 
can also determine pulmonary kinetics (4, 5). We have used their technique 
to analyze data from an in vivo study. The average capillary mean transit 
time, using an indirect technique, of 1.1 (+0.57) sec in the present study is 
in agreement with the reports of others. Audi et aL reported a mean of 
3.18 sec in the isolated perfused dog lung using a multiple indicator dilution 
method (4). Capen et al. used both in vivo microscopy and diffusing capacity 
techniques to estimate pulmonary capillary transit times and obtained values 
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of 1.75 sec and 1.85 sec, respectively for the direct and indirect techniques 
(18). On the basis of a combined morphometric and indicator dilution tech- 
nique, Hogg et al. reported a mean pulmonary capillary transit time of 
1.37 sec with individual values in the range of 0.18 sec to 7.6 see, depending 
on the region of the lung they investigated (19). A vertical gradient of 
mean pulmonary capillary transit times in different regions of the lung of 
anesthetized dogs has been reported by Wagner et al. who used a direct 
technique to determine mean times of 12.3 sec, 3.1 sec, and 1.6 sec for the 
upper, middle, and lower lung, respectively (20). Reduced blood flow in the 
upper lung in comparison to the gravity-dependent regions is reflected by 
fewer capillaries and longer transit times (20,21). Given these distributions 
of observed transit times, it is not surprising that these findings would be 
reflected in kinetic heterogeneity such as that seen in the present study. 
Others have proposed models with parallel heterogeneity to explain the 
distribution of flows and transit times in the pulmonary circulation (22,23) 
but it remains to be determined whether the distribution of transit times 
that we model define physiologic reality. 
In their description of the estimation technique for capillary transit 
variables, Audi et al. (4) stated that the technique is not very robust when 
only two extravascular markers with flow-limited distribution are used in 
each experiment and suggested that improved parameter confidence could 
be obtained by increasing the number of markers. We also found parameter 
estimation to be unsatisfactory. Specifically, in one experiment we could not 
get convergence on a solution and in the others the fractional standard 
deviations (FSDs) for the parameter estimates all exceeded unity with many 
in excess of 2.0. Because we did not have the option of increasing the number 
of extravascular marker drugs, we instead combined the data from multiple 
experiments in a naive pooled data analysis technique in which the estimates 
of extravascular transit time, variance, and skewness for both drugs in all 
dogs were combined and fit simultaneously to a single model. We, therefore, 
cannot recommend that the technique be used in vivo with only two extravas- 
cular indicators in an experiment in which one wishes to estimate the capil- 
lary transit variables in an individual. 
Detailed tissue drug uptake models are normally restricted to in vitro 
paradigms in order to both control drug administration and blood sampling 
and eliminate the confounding effect of recirculation. While the sites of drug 
administration and sampling for in vivo pulmonary tissue drug uptake 
studies can be controlled easily, the difficulty of recirculation remains. 
The dilemma presented by recirculation is most evident for a drug like 
alfentanil because its significant pulmonary uptake prolongs its mean 
transit time and broadens its first-pass peak (i.e., increases its variance). 
Blood ICG begins to recirculate during the early downstroke of the initial 
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alfentanil appearance curve (Figs. 3a-d), therefore, beginning at this 
point, alfentanil disposition includes both first-pass and recirculation data. 
In cases in which the pulmonary uptake of the drug of interest is extensive, 
hence recireulation occurs relatively quickly, the present modeling technique 
will be able to characterize the curve accurately but may not yield estimates 
that would be valid for characterizing details of pulmonary uptake with a 
single sampling site. 
Simple examination of the primary concentration vs. time data may be 
insufficient to determine conclusively whether a particular data set will yield 
meaningful parameters for the description of pulmonary drug disposition. 
We have followed the procedure of previous investigators (1,2) and excluded 
drug concentration data when there was evidence of drug recirculation. This 
data rejection procedure would be expected to result in a poor characteriza- 
tion of the actual shape of the first-pass drug concentration history (loss of 
later portions with longer half-lives, yielding underestimation of AUC) for 
drugs with longer mean transit times due to their high pulmonary uptake. 
Based on studies in an isolated, perfused rat hindlimb, Zhen et al. (24) has 
suggested that if the ratio of the apparent dose, calculated as the product 
of blood flow and single-pass AUC, to the actual dose is less than 0.8, then 
the resultant kinetic parameter estimates related to tissue uptake (i.e., m t t  
and Vd) should be considered invalid. With poor dose recovery, two poten- 
tially important processes remain uncharacterized: actual elimination by the 
studied organ or the presence of a large, slowly equilibrating compartment. 
Even under conditions without recirculation and relatively long outflow 
sampling periods, more than 20% of certain basic drugs (e.g., propranolol) 
were retained within the tissue. In the present study in which plasma rather 
than blood concentrations were determined, Eq. (27) was used to estimate 
relative drug recovery. 
The blood/plasma partition coefficient of 0.7 for alfentanil in rats 
reported by Bj6rkman et al. (25) corresponds to an RBC/plasma partition 
ratio of 0.33, assuming a hematocrit of 0.45. Using 0.33 as the RBC/plasma 
partition ratio it would be expected that the alfentanil dose calculated as 
the product of the plasma AUC and cardiac output would be 1.33 mg. This 
corresponds well with the 1.28 • 0.16 mg observed in the present study and 
indicates that alfentanil pulmonary tissue distribution was well characterized 
and that significant metabolism in pulmonary tissue is unlikely. Similarly, 
based on a RBC/plasma partition ratio of 0.82 reported for dogs by Clausen 
et al. on the basis of standard in vitro equilibration techniques (26), one 
would expect a plasma apparent antipyrine dose recovery of 26.8 mg. Again, 
this corresponds well with the 26.7 • 3.0 mg observed in the present study 
and is consistent with the ability of first-pass antipyrine data to adequately 
characterize pulmonary tissue distribution (26). 
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The pulmonary capillary transit analyses make use of the higher order 
moments of the first-pass outflow curves, Eqs. (13) and (14). Because it is 
the nature of these higher order moments to be heavily time-weighted, one 
might expect that any error introduced by model extrapolation beyond the 
data, necessitated by recirculation, would be maximally exposed in this ana- 
lysis. In Fig. 4 it is apparent that the antipyrine extravascular mtts vary 
only slightly among the dogs, whereas those for alfentanil are more widely 
separated. Possible alternate interpretations of these results are that the 
pulmonary tissue interaction of alfentanil is more variable than that of anti- 
pyrine or that there is a greater degree of uncertainty in the higher order 
moments of alfentanil because its longer mtts compared to antipyrine results 
in greater portions of its first-pass curves being in the extrapolated segments. 
This is consistent with the FSDs associated with the parameter estimates of 
the pulmonary capillary transit analysis in which the FSD of 
skew>variance>MTT (Table II). Nevertheless, the problem of model 
extrapolation beyond the data does not appear to affect greatly the ability 
of these in vivo data to estimate pulmonary capillary kinetics as these results 
(see Table II) agree with more direct observations of others in dogs (4). 
However, further analysis with a nonrecirculating system would be required 
to determine rigorously the significance of these issues. 
We have developed a pharmacokinetic technique that can be used to 
characterize the first-pass arterial concentration vs. time relationship for 
multiple drugs or markers given by right artrial bolus injection. This model 
has two parallel linear chains (or tanks-in-series) and directly corresponds 
to a sum of two Erlang or gamma distributions. The Erlang and gamma 
functions are convenient because they characterize the lagged, right-skewed 
frequency distributions that are typical of plasma drug concentration histo- 
ries obtained from single-pass tissue distribution studies and because higher- 
order moments are readily calculated from the primary parameters. We have 
provided the algebraic derivations that are needed to calculate the higher 
order moments for a system of two parallel pathways. Finally, we have 
shown that data obtained in vivo and analyzed using these techniques pro- 
vides reasonable physiologic estimates of cardiac output, thoracic blood 
volume, pulmonary extravascular water, and the distribution of pulmonary 
capillary transit times. Furthermore, it may provide a tool for investigating 
the variability in pulmonary uptake of a drug among individuals. Our results 
suggest that comparison of in vivo and in vitro RBC/plasma drug partition- 
ing and examination of an analysis of pulmonary capillary kinetics may help 
resolve whether kinetic estimates of a drug's apparent pulmonary tissue mtt  
and pulmonary distribution volume, determined from first-pass data, are 
valid. This approach should prove useful in the examination of the physio- 
logic basis of differences in drug response during and following rapid intra- 
venous infusion, particularly if there is significant pulmonary uptake. 
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